Karuna Therapeutics Operating Income

Karuna Therapeutics's operating income stands at $-490M as of December 2023. That compares with $-290M in the prior-year period — down 70.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Karuna Therapeutics reported $-490M in operating income versus $-290M a year earlier — a 70.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-290M in the prior-year period — down 70.8% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Karuna Therapeutics's operating income evolved across reporting periods, while the comparison chart places KRTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. Karuna Therapeutics's reading of $-490M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.